Filters
Sort by
An Open-label Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) Who Participated in Study IMR-SCD-102

This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102).

Locations

1 United States site

Age

> 18 Years

Genotypes

HbSS

Phase

Phase 2

LEARN MORE
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)

The goal of the study is to evaluate the efficacy and safety of crizanlizumab in SCD patients with priapism.

Locations

2 United States sites

Age

> 16 Years

Genotypes

HbSS, HbSC

Phase

Phase 2

LEARN MORE
A Phase 1/2 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health and During Acute Vaso-Occlusive Crisis

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of SHP655 in participants with baseline health sickle cell disease (SCD) and SCD with acute vaso-occlusive crisis (VOC).

Age

18 to 65 Years

Genotypes

HbSS

Phase

Phase 1/Phase 2

LEARN MORE
Validation of a Point-of-care Screening Tool for Children With Sickle Cell Disease

Sickle cell disease is very common in Nigeria.

Locations

4 United States sites

3 Nigeria sites

Age

6 to 60 Years

Phase

N/A

LEARN MORE
A Comprehensive Program to Increase Sickle Cell Trait Knowledge and Awareness Among Parents of Infants Identified in Newborn Screening

This is a study for parents of infants with Sickle Cell Trait (SCT) identified by newborn screening who are referred and present for in person SCT education at the Institution.

Locations

1 United States site

Age

> 18 Years

LEARN MORE
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of Deferoxamine Intradermal Delivery Patch (DIDP) in Chronic Sickle Cell Leg Ulcers

Approximately 60 subjects will be enrolled into this double-blind, placebo-controlled study for the Deferoxamine Intradermal Delivery Patch (DIDP).

Age

> 18 Years

Genotypes

SC

Phase

Phase 1/Phase 2

LEARN MORE
An Open-Label 12-Week Food Study to Assess the Safety, Tolerability, And Physiological Effects of An Amino Acid Food Product, AXA4010, In Subjects With Sickle Cell Disease.

This is an open-label study to understand the safety and tolerability of AXA4010, a novel composition of amino acids in adult and adolescent subjects with sickle cell disease over 12 weeks.

Locations

4 United States sites

Age

> 12 Years

Phase

N/A

LEARN MORE
Assessment of Implementation of the Automated Erythrocytapheresis in the Outcome of Egyptian Sickle Cell Disease Patients: Single Center Experience

Improvements of health infrastructure, preventive care and clinical treatment have reduced the morbidity and mortality of sickle cell disease (SCD).

Locations

1 Egypt site

Age

2 to 30 Years

Phase

N/A

LEARN MORE
Metabolic and Vascular Response to Exercise in Sickle Cell Trait Carriers: Effect of Hot Environment

The heterozygous form of sickle cell disease is clinically asymptomatic.

Locations

1 Guadeloupe site

Age

18 to 30 Years

Phase

N/A

LEARN MORE
Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization- mESH Study

This project proposes to develop, test and evaluate targeted interventions to improve clinical provider prescribing of and patient adherence to hydroxyurea (HU).

Locations

8 United States sites

Age

15 to 45 Years

Genotypes

SS, SC

Phase

N/A

LEARN MORE
Site is under construction